Product image of Gribero (Dabigatran Etexilate) supplied by GNH India

Gribero

Active Ingredient:
Dabigatran Etexilate
Origin:
EU

Gribero (Dabigatran Etexilate)

Gribero is a prescription oral medication that contains the active ingredient dabigatran etexilate, a direct thrombin inhibitor used as an anticoagulant. It is marketed in the European Union and is supplied in tablet form for oral administration. The product is intended for patients who require prevention of clot‑related events, such as stroke associated with non‑valvular atrial fibrillation, and for treatment of venous thromboembolism.

Manufacturer / TM Owner

Sandoz D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Gribero is indicated for several anticoagulation purposes in adult patients. It is commonly prescribed to reduce the risk of clot‑related complications in specific cardiovascular and venous conditions.

  • Prevention of stroke and systemic embolism in non‑valvular atrial fibrillation.
  • Treatment of acute deep vein thrombosis (DVT).
  • Treatment of acute pulmonary embolism (PE).
  • Secondary prevention of recurrent DVT and PE after initial therapy.
  • Long‑term anticoagulation in patients with a history of venous thromboembolism.

Side Effects

Side effects of Gribero vary in frequency and severity. Patients should be aware of both common and serious reactions that may occur during therapy.

Common

  • Minor gastrointestinal discomfort such as dyspepsia or nausea.
  • Minor bruising or bleeding from gums.
  • Nosebleeds (epistaxis).
  • Headache.
  • Diarrhea.

Serious

  • Major bleeding events, including intracranial hemorrhage.
  • Gastrointestinal bleeding requiring medical attention.
  • Allergic reactions such as rash or angioedema.
  • Liver enzyme elevations indicating hepatic involvement.

Precautions & Warnings

Before starting Gribero, certain health considerations should be reviewed to minimize risks. Patients and clinicians should evaluate the following factors:

  • History of active or recent major bleeding.
  • Severe renal impairment or fluctuating kidney function.
  • Planned surgical or invasive procedures.
  • Concomitant use of other anticoagulants or antiplatelet agents.
  • Uncontrolled hypertension.
  • Pregnancy or breastfeeding status, where safety data are limited.

Avoid Interactions

Gribero can interact with other medicines, affecting its anticoagulant effect. Interactions are grouped by the level of risk.

Avoid

  • Strong P‑glycoprotein inhibitors (e.g., ketoconazole, itraconazole).
  • Potent CYP3A4 inhibitors (e.g., clarithromycin, ritonavir).
  • Other anticoagulants or antiplatelet drugs (e.g., warfarin, clopidogrel) unless specifically directed.

Use with caution

  • NSAIDs and selective COX‑2 inhibitors (e.g., ibuprofen, celecoxib).
  • Certain antacids containing aluminum or magnesium.
  • Herbal supplements such as St. John’s wort.
  • Medications that affect renal function (e.g., diuretics).

Frequently Asked Questions

Gribero is used to reduce the risk of stroke and systemic embolism in patients who have non‑valvular atrial fibrillation.

Yes, Gribero is indicated for the acute treatment of deep vein thrombosis and for secondary prevention of recurrent DVT after initial therapy.

Gribero can be taken with or without food; however, consistent administration relative to meals helps maintain stable drug levels.

Dabigatran etexilate is a reversible direct thrombin inhibitor that blocks conversion of fibrinogen to fibrin, thereby inhibiting clot formation.

Common side effects include mild gastrointestinal upset, nosebleeds, minor bruising, headache, and diarrhea.

Patients are generally advised to discontinue Gribero 24–48 hours before elective surgery, but the exact timing should be determined by the treating physician.

Unlike warfarin, routine coagulation monitoring is not required for Gribero, although periodic renal function tests may be recommended.

Gribero is contraindicated in patients with severe renal impairment; dose adjustment or alternative therapy may be needed for moderate impairment.

The patient should seek immediate medical attention; healthcare providers may use specific reversal agents such as idarucizumab in severe cases.

Patients should avoid non‑steroidal anti‑inflammatory drugs (NSAIDs) and high‑dose aspirin unless directed by a healthcare professional.

The safety of Gribero during pregnancy has not been established, and it should only be used if the potential benefit justifies the potential risk to the fetus.

Gribero tablets should be stored at room temperature, away from moisture and direct sunlight, and kept out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.